ZBIO — Zenas Biopharma Balance Sheet
0.000.00%
Last trade - 00:00- $1.23bn
- $966.63m
- $10.00m
Annual balance sheet for Zenas Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 67.2 | 56.9 | 351 | 343 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 68.4 | 59.8 | 356 | 351 |
| Net Property, Plant And Equipment | 1.8 | 1.01 | 1.19 | 1.39 |
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 74.6 | 68.2 | 370 | 384 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 26 | 23.3 | 57.3 | 62.6 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 26.8 | 43.8 | 57.5 | 141 |
| Redeemable Preferred Stock | ||||
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 47.8 | 24.4 | 312 | 242 |
| Total Liabilities & Shareholders' Equity | 74.6 | 68.2 | 370 | 384 |
| Total Common Shares Outstanding |